MRK · 10-Q · 2026Q3 · Full report

Restructuring and Cost Reduction

Merck & Co., Inc. · 2026-11-04 · Importance 52 · Surprise 42 · No source text

Merck’s July 2025 restructuring program is expected to incur approximately $3.0 billion in cumulative pretax costs, about 60% cash, and generate approximately $1.7 billion in annual savings, substantially realized by the end of 2027. The program includes reductions in sales, administrative, and R&D positions, a smaller global real estate footprint, and manufacturing-network optimization; manufacturing actions are expected to be substantially completed by the end of 2029. It forms part of a multiyear optimization initiative targeting $3.0 billion in annual savings by the end of 2027, to be fully reinvested in strategic growth areas. The January 2024 restructuring program carries estimated cumulative pretax costs of approximately $4.0 billion and is expected to produce approximately $750 million in cumulative annual net savings by the end of 2031.

Key facts

• Merck's multiyear optimization initiative is anticipated to achieve $3.0 billion in annual cost savings by the end of 2027, fully reinvested in strategic growth areas. source
• The 2025 Restructuring Program is expected to produce approximately $1.7 billion in annual cost savings, substantially realized by the end of 2027. source
• The 2025 Restructuring Program is estimated to incur approximately $3.0 billion of cumulative pretax costs, approximately 60% of which will be cash. source
• The 2025 Restructuring Program, approved in July 2025, expects most actions to be largely completed by the end of 2027, except certain manufacturing actions expected to be substantially completed by the end of 2029. source
• Aggregate pretax restructuring-program costs were $581 million in Q3 2026 versus $390 million in Q3 2025, and $1.4 billion in the first nine months of 2026 versus $1.3 billion in the same 2025 period. source

Impact estimates